Qisda Corporation (Stock Symbol: 2352) will subscribe to 4,500,000 privately placed shares of our company at a price of NT$54 per share. This private placement will reach 6.42% of our company’s paid-in capital and make Qisda to be one of our top 10 shareholders.
We are honored to collaborate with Qisda Corporation.
In addition to our ongoing efforts in new drug development, we look forward to having broader collaboration with Qisda in the ophthalmology sector of the healthcare industry. Through leveraging Qisda Healthcare Business Group’s strengths in distribution channels, we aim to explore greater business opportunities and create a win-win situation for both parties.
